NK

1. A compound having the formula (I):

or a pharmaceutically-acceptable salt thereof, wherein

Ar 1 and Ar 2 are each

X 1 is —O—,

R 1 and R 2 are each independently selected from the group consisting of H, C 1 –C 6 alkyl, hydroxy(C 1 –C 3 alkyl), C 3 –C 8 cycloalkyl, —CH 2 F, —CHF 2 and —CF 3 ; or R 1 and R 2 , together with the carbon atom to which they are both attached, form a C 3 to C 6 alkylene ring; or R 1 and R 2 , together with the carbon atom to which they are both attached, form a C═O group;

R 3 is selected from the group consisting of H, C 1 –C 6 alkyl, hydroxy(C 1 –C 3 alkyl), C 3 –C 8 cycloalkyl, —CH 2 F, —CHF 2 and —CF 3 ;

each R 6 is independently selected from the group consisting of H, C 1 –C 6 alkyl and —OH;

each R 7 is independently selected from the group consisting of H and C 1 –C 6 alkyl;

n 2 is 2;

R 4 and R 5 , together with the carbon atom to which they are both attached, form a 5- or 6-membered heterocycloalkyl ring selected from the group consisting of:

wherein said 5- or 6-membered heterocycloalkyl ring is optionally substituted with from 1 to 6 substituents independently selected from the group consisting of R 30 and R 31 ;

R 8 , R 9 and R 10 are each independently selected from the group consisting of H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, —OR 12 , halogen, —CN, —NO 2 , —CF 3 , —CHF 2 , —CH 2 F, —CH 2 CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 F, —OCH 2 CF 3 , —COOR 12 , —CONR 21 R 22 , —OC(O)NR 21 R 22 , —OC(O)R 12 , —NR 21 COR 12 , —NR 21 CO 2 R 15 , —NR 21 CONR 21 R 22 , —NR 21 SO 2 R 15 , —NR 21 R 22 , —SO 2 NR 21 R 22 , —S(O) n6 R 15 , and (R 19 ) r -aryl;

R 12 is H, C 1 –C 6 alkyl or C 3 –C 8 cycloalkyl;

R 13 and R 14 are each independently selected from the group consisting of H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl, —CH 2 CF 3 , and aryl;

n 6 is 0, 1 or 2;

R 15 is C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, —CF 3 or —CH 2 CF 3 ;

R 18 is H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl, hydroxy(C 2 –C 6 )alkyl or —P(O)(OH) 2 ;

each R 19 is a substituent on the aryl ring to which it is attached, and is independently selected from the group consisting of H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, C 1 –C 6 alkoxy, —OH, halogen, —CN, —NO 2 , —CF 3 , —CHF 2 , —CH 2 F, —OCF 3 , —OCHF 2 , —OCH 2 F, —O—(C 1 –C 6 alkyl), —O—(C 3 –C 8 cycloalkyl), —COOR 12 , —CONR 21 R 22 , —OC(O)NR 21 R 22 , —OC(O)R 12 , —NR 21 R 22 , —NR 21 COR 12 , —NR 21 CO 2 R 12 , —NR 21 CONR 21 R 22 , —NR 21 SO 2 R 15 and —S(O) n6 R 15 ;

R 21 and R 22 are each independently selected from the group consisting of H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl and benzyl;

R 23 and R 24 are each independently selected from the group consisting of H and C 1 –C 6 alkyl; or

R 23 and R 24 , together with the carbon atom to which they are both attached, form a C═O or cyclopropyl group;

R 27 is H, —OH or C 1 –C 6 alkyl;

R 28 and R 29 are each independently selected from the group consisting of H and C 1 –C 2 alkyl; or

R 30 and R 31 are each independently selected from the group consisting of H, —OH, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl and —C(O)NR 13 R 14 ; or

R 30 and R 31 , together with the carbon atom to which they are both attached, form ═O, ═S, a cyclopropyl ring or ═NR 36 ;

R 32 and R 33 are each independently selected from the group consisting of H and C 1 –C 6 alkyl;

R 34 is H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl or hydroxy(C 2 –C 6 )alkyl;

R 35 is H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl, —P(O)(OH) 2 , allyl, hydroxy(C 2 –C 6 )alkyl, (C 1 –C 6 )alkoxy(C 1 –C 6 )alkyl, —SO 2 R 15 or —(CH 2 ) 2 —N(R 12 )—SO 2 —R 15 ;

R 36 is H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl, —NO 2 , —CN or OR 12 ;

R 37 is 1 to 3 substituents independently selected from the group consisting of H, C 1 –C 6 alkyl, —OH, C 1 –C 6 alkoxy and halogen;

r is 1 to 3;

X 2 is —NR 35 —, —O—, —S—, —S(O)—, —SO 2 —, —CH 2 —, —CF 2 — or —CR 12 F—;

X 3 is —NR 34 —, —N(CONR 13 R 14 )—, —N(CO 2 R 13 )—, —N(SO 2 R 15 )—, —N(COR 12 )—, —N(SO 2 NHR 13 )—, —O—, —S—, —S(O)—, —SO 2 —, —CH 2 —, —CF 2 — or —CR 12 F—;

n 3 is 1 to 5; and

n 5 is 1 to 3;

or a diastereomer, enantiomer, stereoisomer, regiostereomer, rotomer, or tautomer thereof.

2. The compound or salt according to claim 1 , wherein for Ar 2 , at least two of R 8 , R 9 and R 10 are each —CF 3 .

3. The compound or salt according to claim 1 , wherein for Ar 1 , R 8 , R 9 and R 10 are each independently selected from the group consisting of H, —OH and halogen.

4. The compound or salt according to claim 1 represented by the formula

wherein for Ar 2 , R 8 and R 9 are independently selected from the group consisting of —CF 3 , —CHF 2 , —CH 2 F, halogen, C 1 –C 6 alkyl, —OCF 3 and —OR 12 , and for Ar 1 , R 9 and R 10 are independently selected from the group consisting of H, —OH and halogen.

5. The compound or salt according to claim 1 , where the 5- or 6-membered ring is selected from the group consisting of

wherein R 35 is H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, or (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl; n 5 is 1 or 2; X 2 is —CH 2 —, or —O—, R + is H, C 1 –C 6 alkyl or C 3 –C 8 cycloalkyl; and R 31 is H, —OH or C 1 –C 6 alkyl.

6. The compound or salt according to claim 1 , where the 5- to 6-membered ring is:

wherein R 30 is H, C 1 –C 6 alkyl or C 3 –C 8 cycloalkyl; R 31 is H, —OH or C 1 –C 6 alkyl; each R 35 is independently selected from the group consisting of H, C 1 –C 6 alkyl, C 3 –C 8 cycloalkyl, and (C 3 –C 8 )cycloalkyl(C 1 –C 6 )alkyl; n 4 is 2 or 3 and n 7 is 0.

7. The compound or salt according to claim 5 wherein the 5- to 6-membered ring is selected from the group consisting of

8. The compound according to claim 6 , wherein the 5- to 6-membered ring is

9. The compound or salt according to claim 1 , wherein the compound is selected from the group consisting of:

thereof.

10. The compound or salt according to claim 1 , wherein the compound is:

11. The compound or salt according to claim 1 , wherein the compound is:

12. The compound or salt according to claim 1 , wherein the compound is:

13. The compound or salt according to claim 1 , wherein the compound is:

14. The compound or salt according to claim 1 , wherein the compound is:

15. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in a pharmaceutically acceptable carrier.

16. A method of treating emesis comprising administering to a patient an effective amount of at least one compound or salt of claim 1 .

17. A method of treating cough comprising administering to a patient an effective amount of at least one compound or salt of claim 1 .